


# Stabilis



## Aztreonam



Tradename

Azactam	Australia, Austria, Belgium, Brazil, Chile, Colombia, Denmark, Ecuador, Finland, France, Germany, Great Britain, Greece, Ireland, Italy, Japan, Luxembourg, Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland, United Arab Emirates, United States of America
Azaxil	Brazil
Azthreonam	Argentina, Brazil, Chile, Colombia, Peru, United States of America, Venezuela
Barex	Spain
Cayston	Belgium, Canada, Germany, Spain, Switzerland, United States of America
Monobac	Mexico
Namy	India
Primbactam	Italy
Treonam	Peru
Urobactam	Spain
Vibactam	Peru



### Stability in solutions

		60 mg/ml	-20°C		28			1064
		60 mg/ml	4°C		8			1064
		20 mg/ml	25°C		48			432
		60 mg/ml	-20°C		180			1064
		60 mg/ml	37°C		24			1064
		60 mg/ml	4°C		70			1064
		10 & 20 mg/ml	25°C		48			422
		10 & 20 mg/ml	4°C		7			422

PVC		10 mg/ml	24°C		4			258
PVC		10 mg/ml	5°C		4			258
PVC		20 mg/ml	-20°C		120			1233
PVC		20 mg/ml	4°C		120			1233
PVC		0,5 mg/ml	25°C		14			4456
PVC		0,5 mg/ml	37°C		1			4456
PVC		0,5 mg/ml	6°C		14			4456
PVC		0,4 mg/ml	25°C		3			4456
PVC		0,4 mg/ml	37°C		1			4456
PVC		0,4 mg/ml	6°C		14			4456
PVC		0,5 mg/ml	25°C		3			4456
PVC		0,5 mg/ml	37°C		2			4456
PVC		0,5 mg/ml	6°C		14			4456
PVC		0,5 mg/ml	25°C		3			4456
PVC		0,5 mg/ml	37°C		1			4456
PVC		0,5 mg/ml	6°C		14			4456
PP		125 mg/ml	20-25°C		48			4634
PP		120 mg/ml	25°C		12			4326
PP		20 mg/ml	25°C		48			644
PP		40 mg/ml	25°C		12			4326
PI		5 & 20 mg/ml	25°C		24			604
PI		5 & 20 mg/ml	4°C		14			604
PI		50 mg/ml	37°C		48			4634
?		100 mg/ml	37°C		24			2042



## Stability of mixtures

		8,6 mg/ml	23°C		Ranitidine hydrochloride : 0,5 mg/ml	4		360
		20 mg/ml	25°C		Clindamycin phosphate : 9 mg/ml	48		432
		8,6 mg/ml	22°C-23°C		Ranitidine hydrochloride : 0,5 mg/ml	4		360
		200 mg/ml	25°C		Clindamycin phosphate : 60 mg/ml	48		644
PVC		10 & 20 mg/ml	22°C-23°C		Clindamycin phosphate : 3 & 6 mg/ml	48		419

PVC		10 & 20 mg/ml	23°C-25°C		Cefazolin sodium : 5 & 20 mg/ml	48		426
PVC		10 & 20 mg/ml	25°C		Gentamicin sulfate : 0,2 & 0,8 mg/ml	8		19
PVC		10 & 20 mg/ml	25°C		Cefoxitin sodium : 10 & 20 mg/ml	12		19
PVC		10 & 20 mg/ml	25°C		Tobramycin sulfate : 0,2 & 0,8 mg/ml	48		19
PVC		4 mg/ml	32°C		Vancomycin hydrochloride : 1 mg/ml	7		284
PVC		10 & 20 mg/ml	4°C		Clindamycin phosphate : 3 & 6 mg/ml	7		419
PVC		10 & 20 mg/ml	4°C		Tobramycin sulfate : 0,2 mg/ml	7		19
PVC		10 & 20 mg/ml	4°C		Tobramycin sulfate : 0,2 & 0,8 mg/ml	7		19
PVC		10 & 20 mg/ml	4°C		Cefoxitin sodium : 10 & 20 mg/ml	7		19
PVC		4 mg/ml	4°C		Vancomycin hydrochloride : 1 mg/ml	31		284
PVC		10 & 20 mg/ml	4°C		Gentamicin sulfate : 0,2 & 0,8 mg/ml	24		19
PVC		10 & 20 mg/ml	4°C-5°C		Cefazolin sodium : 5 & 20 mg/ml	7		426
PVC		4 mg/ml	23°C		Vancomycin hydrochloride : 1 mg/ml	31		284
PVC		10 mg/ml	24°C		Ampicillin sodium - sulbactam sodium : 20 mg/ml	24		258
PVC		10 mg/ml	5°C		Ampicillin sodium - sulbactam sodium : 20 mg/ml	84		258
PVC		4 mg/ml	23°C		Vancomycin hydrochloride : 1 mg/ml	14		284
POF		20 mg/ml	23°C		Linezolid : 2 mg/ml	7		1658
POF		20 mg/ml	4°C		Linezolid : 2 mg/ml	7		1658
		16,7 mg/ml	22°C-28°C		Daptomycin : 16,7 mg/ml	2		1937



## Factors which affect stability

				2263
--	--	--	--	------



## Compatibility

		Aztreonam : 40 mg/ml Aciclovir sodium : 7 mg/ml	99
		Aztreonam Aciclovir sodium	3595
		Aztreonam : 40 mg/ml Allopurinol sodium : 3 mg/ml	307
		Aztreonam : 40 mg/ml Amifostine : 10 mg/ml	3
		Aztreonam Amikacin sulfate	3549

		Aztreonam : 40 mg/ml Amikacin sulfate : 5 mg/ml		99
		Aztreonam : 40 mg/ml Aminophylline : 2.5 mg/ml		99
		Aztreonam : 40 mg/ml Amphotericin B : 0.6 mg/ml		99
		Aztreonam : 40 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Aztreonam : 40 mg/ml Ampicillin sodium : 20 mg/ml		99
		Aztreonam : 10 & 20 mg/ml Ampicillin sodium : 5 & 20 mg/ml		422
		Aztreonam : 40 mg/ml Ampicillin sodium - sulbactam sodium : 20/10 mg/ml		99
		Aztreonam : 40 mg/ml Amsacrine : 1 mg/ml		253
		Aztreonam : 200 mg/ml Azithromycine : 2 mg/ml		1800
		Aztreonam : 40 mg/ml Bivalirudin : 5 mg/ml		1713
		Aztreonam : 40 mg/ml Bleomycin sulfate : 1 mg/ml		99
		Aztreonam : 40 mg/ml Bumetanide : 0.04 mg/ml		99
		Aztreonam : 40 mg/ml Buprenorphine hydrochloride : 0.04 mg/ml		99
		Aztreonam : 40 mg/ml Butorphanol tartrate : 0.04 mg/ml		99
		Aztreonam : 40 mg/ml Calcium gluconate : 40 mg/ml		99
		Aztreonam : 40 mg/ml Carboplatin : 5 mg/ml		99
		Aztreonam : 40 mg/ml Carmustine : 1.5 mg/ml		99
		Aztreonam : 20 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Aztreonam : 40 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Aztreonam : 40 mg/ml Cefazolin sodium : 20 mg/ml		99
		Aztreonam : 10 & 20 mg/ml Cefazolin sodium : 5 & 20 mg/ml		426
		Aztreonam : 20 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Aztreonam : 40 mg/ml Cefonicid sodium : 20 mg/ml		99
		Aztreonam : 40 mg/ml Cefoperazone sodium : 40 mg/ml		99
		Aztreonam : 40 mg/ml Cefotaxime sodium : 20 mg/ml		99
		Aztreonam : 40 mg/ml Cefoxitin sodium : 20 mg/ml		99

	Aztreonam : 10 & 20 mg/ml Cefoxitin sodium : 10 & 20 mg/ml		19
	Aztreonam : 40 mg/ml Ceftazidime : 40 mg/ml		99
	Aztreonam : 10 & 20 mg/ml Ceftazidime Avibactam : 8,25 & 50 mg/ml		4548
	Aztreonam : 40 mg/ml Ceftizoxime sodium : 20 mg/ml		99
	Aztreonam : 20 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
	Aztreonam : 40 mg/ml Ceftriaxone disodium : 20 mg/ml		99
	Aztreonam : 40 mg/ml Cefuroxime sodium : 30 mg/ml		99
	Aztreonam : 40 mg/ml Chlormethine hydrochloride : 1 mg/ml		99
	Aztreonam : 40 mg/ml Chlorpromazine hydrochloride : 2 mg/ml		99
	Aztreonam : 40 mg/ml Cimetidine hydrochloride : 12 mg/ml		99
	Aztreonam : 20 mg/ml Ciprofloxacin lactate : 1 mg/ml		500
	Aztreonam : 40 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
	Aztreonam : 40 mg/ml Ciprofloxacin lactate : 1 mg/ml		99
	Aztreonam : 40 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
	Aztreonam : 40 mg/ml Cisplatin : 1 mg/ml		99
	Aztreonam : 10 mg/ml Clindamycin phosphate : 3 mg/ml		419
	Aztreonam : 20 mg/ml Clindamycin phosphate : 6 mg/ml		419
	Aztreonam : 10 mg/ml Clindamycin phosphate : 6 mg/ml		419
	Aztreonam : 40 mg/ml Clindamycin phosphate : 10 mg/ml		99
	Aztreonam : 20 mg/ml Clindamycin phosphate : 9 mg/ml		432
	Aztreonam : 200 mg/ml Clindamycin phosphate : 60 mg/ml		644
	Aztreonam Clindamycin phosphate		3526
	Aztreonam : 20 mg/ml Clindamycin phosphate : 3 mg/ml		419
	Aztreonam : 40 mg/ml Co-trimoxazole : 4/0.8 mg/ml		99
	Aztreonam : 40 mg/ml Cyclophosphamide : 10 mg/ml		99
	Aztreonam : 40 mg/ml Cytarabine : 50 mg/ml		99

	Aztreonam : 40 mg/ml Dacarbazine : 4 mg/ml		99	
	Aztreonam : 40 mg/ml Dactinomycin : 10 µg/ml		99	
	Aztreonam Daptomycin		2271	
	Aztreonam : 16,7 mg/ml Daptomycin : 16,7 mg/ml		1937	
		Aztreonam : 40 mg/ml Daunorubicin hydrochloride : 1 mg/ml		99
	Aztreonam : 40 mg/ml Dexamethasone sodium phosphate : 1 mg/ml		99	
	Aztreonam : 40 mg/ml Dexmedetomidine : 4 µg/ml		1712	
	Aztreonam : 20 & 333 mg/ml Diltiazem hydrochloride : 5 mg/ml		198	
	Aztreonam : 333 mg/ml Diltiazem hydrochloride : 1 mg/ml		198	
	Aztreonam : 40 mg/ml Diphenhydramine hydrochloride : 2 mg/ml		99	
	Aztreonam : 40 mg/ml Dobutamine hydrochloride : 4 mg/ml		99	
	Aztreonam : 40 mg/ml Docetaxel : 0.9 mg/ml		1754	
	Aztreonam : 40 mg/ml Dopamine hydrochloride : 3.2 mg/ml		99	
	Aztreonam : 40 mg/ml Doxorubicin hydrochloride : 2 mg/ml		99	
	Aztreonam : 40 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251	
	Aztreonam : 40 mg/ml Doxycycline hyclate : 1 mg/ml		99	
	Aztreonam : 40 mg/ml Droperidol : 0.4 mg/ml		99	
	Aztreonam : 40 mg/ml Enalaprilate : 0.1 mg/ml		99	
	Aztreonam : 10 mg/ml Enalaprilate : 0.05 mg/ml		1315	
	Aztreonam : 20 mg/ml Eravacycline : 0,6 mg/ml		4434	
		Aztreonam Erythromycin lactobionate		3674
	Aztreonam : 40 mg/ml Etoposide : 0.4 mg/ml		99	
	Aztreonam : 40 mg/ml Etoposide phosphate : 5 mg/ml		1410	
	Aztreonam : 40 mg/ml Famotidine : 2 mg/ml		99	
	Aztreonam : 40 mg/ml Fenoldopam mesylate : 80 µg/ml		1803	
	Aztreonam : 40 mg/ml Filgrastim : 30 µg/ml		99	

	Aztreonam : 40 mg/ml Filgrastim : 30 µg/ml		244
	Aztreonam : 40 mg/ml Floxadine : 3 mg/ml		99
	Aztreonam : 40 mg/ml Fluconazole : 2 mg/ml		99
	Aztreonam : 40 mg/ml Fluconazole : 2 mg/ml		496
	Aztreonam : 40 mg/ml Fludarabine phosphate : 1 mg/ml		492
	Aztreonam : 40 mg/ml Fludarabine phosphate : 1 mg/ml		99
	Aztreonam : 40 mg/ml Fluorouracil : 16 mg/ml		99
	Aztreonam : 40 mg/ml Folate calcium : 2 mg/ml		99
	Aztreonam : 40 mg/ml Foscarnet sodium : 24 mg/ml		1135
	Aztreonam : 40 mg/ml Foscarnet sodium : 24 mg/ml		73
	Aztreonam : 20 mg/ml Fosfomycin : 30 mg/ml		4055
	Aztreonam : 40 mg/ml Furosemide : 3 mg/ml		99
	Aztreonam : 40 mg/ml Gallium nitrate : 0.4 mg/ml		99
	Aztreonam : 40 mg/ml Ganciclovir sodium : 20 mg/ml		99
	Aztreonam : 40 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
	Aztreonam : 40 mg/ml Gentamicin sulfate : 5 mg/ml		99
	Aztreonam : 10 & 20 mg/ml Gentamicin sulfate : 0.2 & 0.8 mg/ml		19
	Aztreonam : 40 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
	Aztreonam : 40 mg/ml Haloperidol lactate : 0.2 mg/ml		99
	Aztreonam : 40 mg/ml Hetastarch : 60 mg/ml		1721
	Aztreonam : 40 mg/ml Ifosfamide : 25 mg/ml		99
	Aztreonam : 40 mg/ml Imipenem - cilastatin sodium : 10 mg/ml		99
	Aztreonam : 40 mg/ml		301
	Aztreonam : 20 mg/ml Heparin sodium : 50 UI/ml		317
	Aztreonam : 40 mg/ml Heparin sodium : 100 UI/ml		99
	Aztreonam : 40 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		99

		Aztreonam : 40 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml		99
		Aztreonam : 40 mg/ml Hydroxyzine dihydrochloride : 4 mg/ml		99
		Aztreonam : 40 mg/ml Idarubicin hydrochloride : 0.5 mg/ml		99
		Aztreonam : 20 mg/ml Insulin : 0.2 UI/ml		129
		Aztreonam : 20 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Aztreonam : 40 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Aztreonam : 40 mg/ml Linezolid : 2 mg/ml		1925
		Aztreonam : 20 mg/ml Linezolid : 2 mg/ml		1658
		Aztreonam : 40 mg/ml Lorazepam : 0.1 mg/ml		99
		Aztreonam : 40 mg/ml Magnesium sulfate : 100 mg/ml		99
		Aztreonam : 40 mg/ml Mannitol : 0.15 mg/ml		99
		Aztreonam : 40 mg/ml Methotrexate sodium : 15 mg/ml		99
		Aztreonam : 40 mg/ml		1415
		Aztreonam : 40 mg/ml Melphalan : 0.1 mg/ml		169
		Aztreonam : 100 mg/ml Meropenem : 50 mg/ml		4319
		Aztreonam : 100 mg/ml Meropenem : 50 mg/ml		4389
		Aztreonam : 40 mg/ml Mesna : 10 mg/ml		99
		Aztreonam : 40 mg/ml Methylprednisolone sodium succinate : 5 mg/ml		99
		Aztreonam : 40 mg/ml Metoclopramide hydrochloride : 5 mg/ml		99
		Aztreonam : 10 & 20 mg/ml Metronidazole : 5 mg/ml		19
		Aztreonam Metronidazole		3547
		Aztreonam : 40 mg/ml Metronidazole : 5 mg/ml		99
		Aztreonam : 40 mg/ml Minocycline hydrochloride : 0.2 mg/ml		99
		Aztreonam : 40 mg/ml Mitomycin : 0.5 mg/ml		99
		Aztreonam : 40 mg/ml Mitoxantrone dihydrochloride : 0.5 mg/ml		99
		Aztreonam : 40 mg/ml Morphine sulfate : 1 mg/ml		99



		Aztreonam : 20 mg/ml Morphine sulfate : 1 mg/ml		62
		Aztreonam : 10 >> 20 mg/ml Nafcillin sodium : 10 >> 20 mg/ml	 	433
		Aztreonam Nafcillin sodium		3547
		Aztreonam : 40 mg/ml Nalbuphine hydrochloride : 10 mg/ml		99
		Aztreonam : 40 mg/ml Netilmicin sulfate : 5 mg/ml		99
		Aztreonam : 10 mg/ml Nicardipine hydrochloride : 0.1 mg/ml	 	1490
		Aztreonam : 40 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Aztreonam : 40 mg/ml Ondansetron hydrochloride : 1 mg/ml		99
		Aztreonam : 20 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Aztreonam : 40 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Aztreonam : 40 mg/ml Pethidine hydrochloride : 4 mg/ml		99
		Aztreonam : 20 mg/ml Pethidine hydrochloride : 10 mg/ml		62
		Aztreonam : 40 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Aztreonam : 40 mg/ml Piperacillin sodium : 40 mg/ml		99
		Aztreonam : 40 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Aztreonam : 20 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Aztreonam : 40 mg/ml Potassium chloride : 100 mEq/l		99
		Aztreonam : 40 mg/ml Prochlorperazine edysilate : 0.5 mg/ml		99
		Aztreonam : 40 mg/ml Promethazine hydrochloride : 2 mg/ml		99
		Aztreonam : 40 mg/ml Propofol : 10 mg/ml		300
		Aztreonam : 20 mg/ml Quinupristine/dalfopristine : 2 mg/ml		1513
		Aztreonam : 40 mg/ml Ranitidine hydrochloride : 2 mg/ml		99
		Aztreonam : 40 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
		Aztreonam : 40 mg/ml Sargramostim : 10 µg/ml		335
		Aztreonam : 40 mg/ml Sargramostim : 10 µg/ml		99
		Aztreonam : 40 mg/ml Sodium bicarbonate : 84 mg/ml		99

		Aztreonam : 40 mg/ml Streptozocin : 40 mg/ml		99
		Aztreonam : 20 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Aztreonam : 20 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Aztreonam : 40 mg/ml Teniposide : 0.1 mg/ml		905
		Aztreonam : 40 mg/ml Teniposide : 0.1 mg/ml		99
		Aztreonam : 20 mg/ml Theophylline : 4 mg/ml		317
		Aztreonam : 40 mg/ml Thiotepa : 1 mg/ml		99
		Aztreonam : 40 mg/ml Thiotepa : 1 mg/ml		249
		Aztreonam : 40 mg/ml Ticarcillin / clavulanic acid : 30 mg/ml		99
		Aztreonam : 10 & 20 mg/ml Tobramycin sulfate : 0.2 & 0.8 mg/ml		19
		Aztreonam : 40 mg/ml Tobramycin sulfate : 5 mg/ml		99
		Aztreonam : 200 mg/ml Vancomycin hydrochloride : 66.67 mg/ml		94
		Aztreonam : 4 mg/ml Vancomycin hydrochloride : 1 mg/ml		284
		Aztreonam : 40 mg/ml Vancomycin hydrochloride : 10 mg/ml		284
		Aztreonam : 40 mg/ml Vancomycin hydrochloride : 10 mg/ml		99
		Aztreonam : 40 mg/ml Vinblastine sulfate : 0.12 mg/ml		99
		Aztreonam : 40 mg/ml Vincristine sulfate : 0.05 mg/ml		99
		Aztreonam : 40 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Aztreonam : 40 mg/ml Zidovudine : 4 mg/ml		337
		Aztreonam : 40 mg/ml Zidovudine : 4 mg/ml		99



## Route of administration





## References

	Type	Publication
3	Journal	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
19	Journal	Bell RG, Lipford LC, Massanari MJ, Riley CM. Stability of intravenous admixtures of aztreonam and cefoxitin, gentamicin, metronidazole, or tobramycin. Am J Hosp Pharm 1986 ; 43: 1444-1453.
59	Journal	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Journal	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
73	Journal	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Journal	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Journal	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
94	Journal	Chandler SW, Folstad J, Trissel LA. Aztreonam-vancomycin incompatibility. Am J Hosp Pharm 1990 ; 47: 1970.
99	Journal	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
129	Journal	Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126.
169	Journal	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	Journal	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
244	Journal	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Journal	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.

251	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Journal	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
258	Journal	Belliveau PP, Nightingale CH, Quintiliani R. Stability of aztreonam and ampicillin sodium-sulbactam sodium in 0.9% sodium chloride injection. Am J Hosp Pharm 1994 ; 51: 901-904.
284	Journal	Trissel LA, Xu QA, Martinez JF. Compatibility and stability of aztreonam and vancomycin hydrochloride. Am J Health-Syst Pharm 1995 ; 52: 2560-2564.
285	Journal	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
299	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Journal	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Journal	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
317	Journal	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
334	Journal	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Journal	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
337	Journal	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
360	Journal	Inagaki K, Gill MA, Okamoto MP, Takagi J. Stability of ranitidine hydrochloride with aztreonam, ceftazidime, or piperacillin sodium during simulated Y-site administration. Am J Hosp Pharm 1992 ; 49: 2769-2772.
419	Journal	James MJ, Riley CM. Stability of intravenous admixtures of aztreonam and clindamycin phosphate. Am J Hosp Pharm 1985 ; 42: 1984-1986.
422	Journal	James MJ, Riley CM. Stability of intravenous admixtures of aztreonam and ampicillin. Am J Hosp Pharm 1985 ; 42: 1095-1100.

426	Journal	Riley CM, James MJ. Stability of intravenous admixtures containing aztreonam and cefazolin. Am J Hosp Pharm 1986 ; 43: 925-927.
432	Journal	Marble DA, Bosso JA, Townsend RJ. Stability of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium, or piperacillin sodium in two intravenous solutions. Am J Hosp Pharm 1986 ; 43: 1732-1736.
433	Journal	Riley CM, Lipford LC. Interaction of aztreonam with nafcillin in intravenous admixtures. Am J Hosp Pharm 1986 ; 43: 2221-2224.
492	Journal	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Journal	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
500	Journal	Tucker DR, Sieradzan R. Visual compatibility of ciprofloxacin lactate with five broad-spectrum antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1910-1911.
604	Manufacturer	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
644	Journal	Marble DA, Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with aztreonam in polypropylene syringes and with cefoperazone sodium, cefonicid sodium, and cefuroxime sodium in partial-fill glass bottles. Drug Intell Clin Pharm 1988 ; 22: 54-57.
905	Journal	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Journal	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1064	Journal	Vinks AATMM, Touw DJ, van Rossen RCJM, Heijeiman HGM, Bakker W. Stability of aztreonam in a portable pump reservoir used for home intravenous antibiotic treatment (HIVAT). Pharm World Sci 1996 ; 18: 74-77.
1135	Journal	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1233	Journal	McLaughlin JP, Simpson C. The stability of reconstituted aztreonam. Br J Pharm Pract 1990 ; 12: 328, 330, 334.
1315	Journal	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	Journal	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Journal	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.

1423	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	Journal	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1513	Manufacturer	Quinupristine / dalfopristine (Synercid®) - Résumé des caractéristiques du produit Monarch Pharmaceuticals Ireland 2006
1625	Journal	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1658	Journal	Zhang Y, Xu QA, Trissel LA, Willimas KY. Compatibility and stability of linezolid injection admixed with aztreonam or piperacillin sodium. J Am Pharm Assoc 2000 ; 40: 520-524.
1712	Journal	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Journal	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Journal	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Journal	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1800	Journal	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Journal	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Journal	Trissel LA, Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1937	Journal	Lai JJ, Brodeur SK. Physical and chemical stability of daptomycin with nine medications. Ann Pharmacotherapy 2004 ; 38: 1612-1616.
1953	Journal	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2042	Journal	Viaene E, Chanteux H, Servais H, Mingeot-Leclerq MP, Tulkens PM. Comparative stability studies of antipseudomonal $\beta$ -lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2233	Journal	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Journal	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.




























2263	Journal	Zajac M, Jelinska A, Cielecka-Piontek J, Oszczapowicz I. Stability of aztreonam in AZACTAM. Il Farmaco 2005 ; 60: 599-603.
2271	Manufacturer	Daptomycine (Cubicin®) Résumé des caractéristiques du produits Novartis 2006
3152	Journal	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3526	Manufacturer	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3547	Manufacturer	Aztréonam (Azactam®) - Résumé des caractéristiques du produit Sanofi-Aventis France 2011
3549	Manufacturer	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3595	Manufacturer	Aciclovir - Summary of Product Characteristics Hospira 2009
3674	Manufacturer	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Journal	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Journal	Asempta T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Journal	Lessard J-J, Caron E, Schérier H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4326	Journal	Curti C, Harti Souab K, Lamy E, Mathias F, Bornet C, Guinard B, Fersing C, Primas N, Albanèse J, Vanelle P. Stability studies of antipyocyanic beta-lactam antibiotics used in continuous infusion. Pharmazie 2019 ; 74: 357-362.
4389	Journal	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévamisentan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4434	Journal	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.

4456	Journal	Tobudic S, Prager I, Kussmann M, Obermüller M, Ursli M, Zeitlinger M, Wiesholzer M, Burgmann H, Poepl W, Reznicek G. Compatibility of aztreonam in four commercial peritoneal dialysis fluids. Scientific reports 2020 10:1788
4528	Journal	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4548	Journal	O'Donnell J.N, Xu A, Lodise T.P. Intravenous Compatibility of Ceftazidime/Avibactam and Aztreonam Using Simulated and Actual Y-site Administration. Clin Ther 2020 ; 42, 8: 1580-1586.
4634	Journal	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4801	Journal	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:





# Dictionary

 Antibiotic	 injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Duration of stability
 Biosimilar	 conflicting data
 References	 Glass
 Water for Injection	 Protect from light
 Day	 NaCl 0,9% or Glucose 5%
 Light	 Hour
 Polyvinyl chloride	 Not specified
 Sodium chloride 0,9%	 Extraneal® (Baxter)
 Nutrineal®	 Physionéal® 1.36 (Baxter)
 Physionéal® 2.27 (Baxter)	 Polypropylen Syringe
 Polyisoprene elastomer	 Elastomer (unspecified)
 Stability of mixtures	 Solvent
 Compound	 Not specified
 Glucose 5%	 Polyolefine
 None	 Factors which affect stability
 Increase	 Induces
 Degradation	 Compatibility
 Immediate precipitation	 Incompatible
 Unspecified incompatibility	 Compatible
 Chemical instability	 Immediate turbidity
 specific solvent	 Parenteral nutrition (binary mixture)
 Turbidity in one hour	 Parenteral nutrition (with lipids)
 Color change after 12 hours	 Color change after 4 hours
 Precipitation after 1 hour	 Precipitation after 6 hours
 Turbidity in 4 hours	 Color change after 1 hour
 Route of administration	 Intravenous



Intravenous infusion



Intramuscular



References



Dictionary